Protalix BioTherapeutics (PLX) Reports In-Line Q3 EPS
Tweet
Share
E-mailGet Alerts PLX Hot Sheet
Price: $2.69 -0.37%
Revenue Growth %: -33.6%
Financial Fact:
OPERATING LOSS: -6.65M
Today's EPS Names:
VIVO, OCCI, ALZN, More
Revenue Growth %: -33.6%
Financial Fact:
OPERATING LOSS: -6.65M
Today's EPS Names:
VIVO, OCCI, ALZN, More
Join SI Premium – FREE
Protalix BioTherapeutics (NYSE: PLX) reported Q3 EPS of ($0.04), in-line with the analyst estimate of ($0.04). Revenue for the quarter came in at $10.34 million versus the consensus estimate of $10 million.
For earnings history and earnings-related data on Protalix BioTherapeutics (PLX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Westinghouse said to seek over $50 billion valuation in planned IPO
- UBS Reiterates Neutral Rating on Intuit (INTU), Says Investor Day Not 'Sentiment-Changing'
- Investing.com’s stocks of the week
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
